Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Jerez De La Frontera – page 6

129 clinical trials in Jerez De La Frontera, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Jerez De La Frontera at a glance
129
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

129 trials in Jerez De La Frontera

Open in trial search

Asthma

Not yet recruiting

Study comparing CHF 5993 (beclometasone/formoterol/glycopyrronium) to fluticasone/salmeterol inhalation in adolescents with uncontrolled asthma on medium-dose inhaled therapy

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Salmeterol
  • Sponsor:Chiesi Farmaceutici S.p.A.

Transitional cell carcinoma

Not yet recruiting

Study Comparing Chemotherapy Before or After Surgery for Patients with Upper Tract Urothelial Carcinoma Using Gemcitabine

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:European Uro-Oncology Group Stichting

Chronic obstructive pulmonary disease

Not recruiting

Study of Verekitug to improve symptoms in patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 kappa monoclonal antibody against CRLF2
  • Sponsor:Upstream Bio Inc.

Paranasal sinus inflammation+1

Not recruiting

Study on the Effectiveness and Safety of Brensocatib for Patients with Chronic Rhinosinusitis Without Nasal Polyps

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Brensocatib
  • Sponsor:Insmed Inc.

Chronic rhinosinusitis with nasal polyps

Not recruiting

Study on Itepekimab for Adults with Chronic Rhinosinusitis and Nasal Polyps

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Chronic rhinosinusitis without nasal polyps

Not recruiting

Study on the Effects of Itepekimab for Patients with Chronic Rhinosinusitis Without Nasal Polyps

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Asthma

Not recruiting

Study on the Effects of Atuliflapon in Adults with Moderate to Severe Uncontrolled Asthma

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atuliflapon
  • Sponsor:AstraZeneca AB

Chronic rhinosinusitis with nasal polyps

Not recruiting

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Small cell lung cancer

Not recruiting

Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Shanghai Henlius Biotech Inc.

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Small cell lung cancer

Not recruiting

Study of Durvalumab for Patients with Limited Stage Small Cell Lung Cancer After Chemoradiotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Astrazeneca Farmaceutica Spain S.A.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Jerez De La Frontera

What the registry says about research in the country

01 Respiratory Medicine

Clinical trials focusing on various respiratory conditions including Acute Respiratory Distress Syndrome, chronic rhinosinusitis, and asthma. Research initiatives are exploring new therapeutic approaches for both adult and pediatric patients.

  • Asthma management in children and adults
  • Nasal polyps treatment evaluation
  • ARDS therapeutic interventions

Studies include testing of novel antibodies and investigating symptom improvement in chronic conditions.

02 Oncology Research

Comprehensive studies targeting various cancer types, with particular focus on breast cancer and lung cancer. Investigations include innovative treatment combinations and targeted therapies.

  • Advanced breast cancer treatments
  • Non-small cell lung cancer therapies
  • Bladder cancer interventions

Research emphasizes personalized treatment approaches and novel drug combinations.

03 Cardiovascular Studies

Research focusing on coronary artery disease and related conditions. Studies evaluate various therapeutic approaches including antiplatelet treatments and surgical interventions.

  • Coronary artery treatments
  • Antiplatelet therapy optimization
  • Arterial dissection management

Trials aim to improve treatment outcomes and reduce complications in cardiac patients.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.